TransMedics Group (NASDAQ:TMDX) Given New $130.00 Price Target at Stifel Nicolaus

Stifel Nicolaus adjusted price targets for three Nasdaq-listed biotech firms. RxSight's target fell from $10.00 to $9.00, retaining a hold rating. Tango Therapeutics' target rose from $15.00 to $24.00, with a buy rating. TransMedics Group's target increased from $115.00 to $130.00, also a hold rating.